{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:47:18Z","timestamp":1793526438319,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019271","name":"Kyorin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020483","name":"Insmed","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020707","name":"Janssen Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023887","name":"Texas A&M University Health Science Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.resinv.2023.12.012","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T17:27:34Z","timestamp":1706203654000},"page":"284-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8239-9275","authenticated-orcid":false,"given":"Kozo","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3815-784X","authenticated-orcid":false,"given":"Mizu","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4157-1112","authenticated-orcid":false,"given":"Taku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tsuyuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna","family":"Jumadilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayton W.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ciesielska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-7450","authenticated-orcid":false,"given":"Naoki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2023.12.012_bib1","first-page":"977","article-title":"Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives","volume":"11","author":"Larsson","year":"2017","journal-title":"Expet Rev Respir Med"},{"key":"10.1016\/j.resinv.2023.12.012_bib2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12879-018-3113-x","article-title":"High mortality in patients with Mycobacterium avium complex lung disease: a systematic review","volume":"18","author":"Diel","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.012_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12931-015-0304-5","article-title":"Health-related quality of life is inversely correlated with C-reactive protein and age in Mycobacterium avium complex lung disease: a cross-sectional analysis of 235 patients","volume":"16","author":"Asakura","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2023.12.012_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.5588\/ijtld.12.0672","article-title":"High-resolution computed tomography and health-related quality of life in Mycobacterium avium complex disease","volume":"17","author":"Maekawa","year":"2013","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.resinv.2023.12.012_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12890-018-0686-5","article-title":"Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease","volume":"18","author":"Yagi","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2023.12.012_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5588\/ijtld.20.0790","article-title":"Health-related quality of life associates with clinical parameters in patients with NTM pulmonary disease","volume":"25","author":"Kawahara","year":"2021","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.resinv.2023.12.012_bib7","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.rmed.2011.08.004","article-title":"Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease","volume":"105","author":"Mehta","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2023.12.012_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106515","article-title":"Longitudinal validity and prognostic significance of the St George\u2019s Respiratory Questionnaire in Mycobacterium avium complex pulmonary disease","volume":"185","author":"Ogawa","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2023.12.012_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2019.05.001","article-title":"Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan","volume":"152","author":"Furuuchi","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2023.12.012_bib10","first-page":"341","article-title":"Epidemiology of adults and children treated for nontuberculous mycobacterial pulmonary disease in Japan","volume":"16","author":"Izumi","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2023.12.012_bib11","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3201\/eid2206.151086","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial disease","volume":"22","author":"Namkoong","year":"2016","journal-title":"Japan. Emerg Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.012_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01855-2016","article-title":"Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases","volume":"49","author":"van Ingen","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2023.12.012_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1513\/AnnalsATS.201607-573OC","article-title":"A laboratory-based analysis of nontuberculous mycobacterial lung disease in Japan from 2012 to 2013","volume":"14","author":"Morimoto","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2023.12.012_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jiac.2015.01.004","article-title":"Increasing patients with pulmonary Mycobacterium avium complex disease and associated underlying diseases in Japan","volume":"21","author":"Ito","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2023.12.012_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.12.012_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.012_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02503-2016","article-title":"Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype","volume":"50","author":"Koh","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2023.12.012_bib18","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.012_bib19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10096-013-1962-1","article-title":"Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis","volume":"33","author":"Xu","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.012_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/azalide therapy for nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2023.12.012_bib21","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1093\/cid\/ciaa729","article-title":"Posttreatment lymphopenia is associated with an increased risk of redeveloping nontuberculous lung disease in patients with Mycobacterium avium complex lung disease","volume":"73","author":"Furuuchi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.012_bib22","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2023.12.012_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.rmed.2019.10.002","article-title":"Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan","volume":"158","author":"Morimoto","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2023.12.012_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/23120541.00097-2019","article-title":"Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease","volume":"6","author":"Izumi","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2023.12.012_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-019-01095-z","article-title":"Amikacin liposome inhalation suspension: a review in Mycobacterium avium complex lung disease","volume":"79","author":"Shirley","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.resinv.2023.12.012_bib26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1445-5994.2011.02452.x","article-title":"Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity","volume":"41","author":"Avent","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.resinv.2023.12.012_bib27","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2023.12.012_bib28","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1513\/AnnalsATS.202008-925OC","article-title":"Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month open-label extension clinical trial","volume":"18","author":"Winthrop","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2023.12.012_bib29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13318-020-00669-7","article-title":"Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-refractory nontuberculous mycobacterial lung disease","volume":"46","author":"Rubino","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.resinv.2023.12.012_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2021.03.070","article-title":"Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure","volume":"160","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2023.12.012_bib31","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf [accessed 26 April 2023]."},{"key":"10.1016\/j.resinv.2023.12.012_bib32","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/AAC.04577-14","article-title":"Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2023.12.012_bib33","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/cid\/cix479","article-title":"Microbiological persistence in patients with Mycobacterium avium complex lung disease: the predictors and the impact on radiographic progression","volume":"65","author":"Pan","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2023.12.012_bib34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejim.2014.03.008","article-title":"Management of nontuberculous mycobacterial infection in the elderly","volume":"25","author":"Mirsaeidi","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.resinv.2023.12.012_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1513\/AnnalsATS.201508-529OC","article-title":"Improvement in quality of life after therapy for Mycobacterium abscessus group lung infection. A prospective cohort study","volume":"13","author":"Czaja","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2023.12.012_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02204-2019","article-title":"Patient reported outcomes for non-tuberculous mycobacterial disease","volume":"55","author":"Loebinger","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2023.12.012_bib37","first-page":"405","article-title":"High prevalence of drug-induced pneumonia in Japan","volume":"50","author":"Azuma","year":"2007","journal-title":"Japan Med Assoc J"},{"key":"10.1016\/j.resinv.2023.12.012_bib38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/pds.1071","article-title":"National differences in reporting \u2018pneumonia\u2019 and \u2018pneumonia interstitial\u2019: an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions","volume":"14","author":"Koo","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.resinv.2023.12.012_bib39","unstructured":"Package insert for ARIKAYCE\u24c7 inhalation 590 mg (amikacin liposome inhalation suspension), http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/150949_6169700G1025_1_06 [accessed 10 January 2023]."}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:33:23Z","timestamp":1761950003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2212534524000054"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2023.12.012","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2023.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}]}}